Oxaliplatin in Cancer Treatment
Author Information
Author(s): J-L Misset
Primary Institution: SMST Hôpital Paul Brousse, Villejuif, France
Hypothesis
Oxaliplatin is effective and safe for treating colorectal and advanced ovarian cancers.
Conclusion
Oxaliplatin is a well-tolerated anticancer drug with a favorable safety profile compared to cisplatin.
Supporting Evidence
- Oxaliplatin has shown a very good safety profile with low haematotoxicity.
- More than 2700 cycles of oxaliplatin plus 5-FU were administered in the study.
- Oxaliplatin was better tolerated than cisplatin in terms of various toxicities.
Takeaway
Oxaliplatin is a medicine that helps treat certain types of cancer and is easier on the body than some other cancer medicines.
Methodology
The study involved a cohort of 490 patients treated with oxaliplatin, either alone or in combination with 5-FU/FA, and compared its safety and efficacy to cisplatin.
Limitations
The study primarily focused on safety and did not provide extensive data on long-term efficacy outcomes.
Participant Demographics
Patients included those with advanced colorectal and ovarian cancers, some heavily pretreated.
Statistical Information
P-Value
0.001
Statistical Significance
p=0.001
Want to read the original?
Access the complete publication on the publisher's website